Previous clinical trials have revealed treatment effect predictor of immune checkpoint inhibitors (ICIs), such as PD‐L1 expression5, 6, 7 and tumor mutation burden8 are positively correlated, and SKT11 and KEAP1 mutations are negatively correlated.9 Here, CD274 is linked to neoplasm.